Skip to content
10-Q

Quarterly Report

Anika Therapeutics, Inc. ANIK

0001171843-25-003019

← back to feed
Filed
May 9, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 14.34M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $53.37M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $55.63M
Current Liabilities Q1 2025 · Mar 31, 2025 $17.9M
Current Liabilities Q1 2025 · Dec 31, 2024 $23.31M
Current Assets Q1 2025 · Mar 31, 2025 $102.51M
Current Assets Q1 2025 · Dec 31, 2024 $113.65M
Total Assets Q1 2025 · Mar 31, 2025 $190.61M
Total Assets Q1 2025 · Dec 31, 2024 $202.74M
Shares Diluted Q1 2025 · Mar 31, 2024 14.7M sh
Stock Repurchased Q1 2025 · Mar 31, 2024 $0
Capex Q1 2025 · Mar 31, 2024 $1.81M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$126K
Stockholders Equity Q1 2025 · Mar 31, 2024 $208.54M
Stockholders Equity Q1 2025 · Dec 31, 2023 $212.27M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.31
Eps Basic Q1 2025 · Mar 31, 2024 −$0.31
Sga Expense restated Q1 2025 · Mar 31, 2024 $15.07M
Rd Expense restated Q1 2025 · Mar 31, 2024 $6.41M
Net Income Q1 2025 · Mar 31, 2024 −$4.51M
Operating Income restated Q1 2025 · Mar 31, 2024 −$2.51M
Gross Profit restated Q1 2025 · Mar 31, 2024 $18.98M
Cost Of Revenue restated Q1 2025 · Mar 31, 2024 $10.05M
Revenue restated Q1 2025 · Mar 31, 2024 $29.02M